SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is experiencing market pressure after its CagriSema obesity drug did not achieve non-inferiority against Eli Lilly's competitor in a recent trial, fueling community debate over its competitive standing. However, strong early demand for its oral Wegovy, coupled with recent regulatory actions against compounded GLP-1 alternatives and ongoing share buybacks, is leading many to see the current sell-off as an overreaction and a potential buying opportunity.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending after receiving FDA approval for BYSANTI, a new chemical entity with patent protection extending to 2044 for bipolar I disorder and schizophrenia. Community sentiment is largely bullish on significant upside potential and a possible short squeeze, though some express caution regarding a recent shelf offering and the drug's similarity to an existing therapy.

Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Redwood City MD.

Arcellx Inc

Recent positive clinical data for Arcellx's multiple myeloma CAR-T therapy, anito-cel, showcases strong efficacy and a differentiated safety profile, driving current conversation. An expanded strategic partnership and investment from Kite (Gilead), combined with the recent lifting of a partial clinical hold, reinforces market confidence and highlights the company's competitive edge in the cell therapy landscape.

Domino's Pizza, Inc. engages in the management of a network of company-owned and franchise-owned pizza stores. It operates through the following segments: U.S. Stores, International Franchise, and Supply Chain. The U.S. Stores segment consists primarily of franchise operations. The International Franchise segment comprises a network of franchised stores. The Supply Chain segment manages regional dough manufacturing and food supply chain centers. The company was founded by James Monaghan and Thomas Stephen Monaghan in 1960 and is headquartered in Ann Arbor, MI.

Dominos Pizza Inc

Dominos Pizza is drawing attention after its Q4 earnings report showcased solid results and strategic investments, further amplified by Berkshire Hathaway's increased stake. The community is actively debating if its focus on value and digital initiatives can continue to drive market share in a competitive restaurant environment.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after reporting stellar Phase 2 S-OLARIS trial results for sonelokimab in axial spondyloarthritis, demonstrating high efficacy and potential disease-modifying effects. This positive data, coupled with a major institutional investor significantly increasing its stake and an anticipated Investor Day, has ignited strong community discussion about its "best-in-class" potential, a potential re-rating, and a short squeeze.

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Gilead Sciences, Inc.

Gilead Sciences is trending as the community processes its solid Q4 earnings beat against conservative 2026 guidance, alongside significant M&A activity including the Arcellx acquisition and key patent settlements for its dominant HIV franchise. Investors are also closely watching developments in its oncology pipeline, such as recent Trodelvy trial results, amid discussions about the company's long-term growth trajectory in a volatile market.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is trending as its Mainnet recently went live and a partnership with Aplix for a Japan-regulated stablecoin was announced, alongside its inclusion in Coinbase's institutional index for perpetual futures. This has sparked a polarized community discussion, with proponents highlighting these fundamental advancements for long-term potential, while critics remain skeptical given the token's continued price performance.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending as Novo Nordisk's latest obesity drug trial underperformed Eli Lilly's, reigniting community discussion that Viking's competitive dual agonist VK2735 is now a highly attractive acquisition or partnership target for pharmaceutical giants eager to capture market share.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending as community debate intensifies around recent tariff rulings and new global levies, with widespread discussion focusing on their economic impact and concerns over the company's financial stability and potential dilution ahead of upcoming disclosures.

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Acadia Pharmaceuticals Inc

Acadia Pharmaceuticals is trending after securing a significant patent victory for its Nuplazid drug, ensuring market exclusivity and prompting multiple analyst upgrades. The community is actively discussing the company's robust, potentially undervalued pipeline in neurological and rare diseases, balancing this against recent EU regulatory challenges for its Rett syndrome treatment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$EFSC &quot;Heads up alert! Only two days until Upcoming earnings on Monday, 10/27/2025 for $EFSC 
Neutral (5.5) 
 
In recent evaluations of Enterprise Financial Services Corp (EFSC), the stock has exhibited a mixed sentiment among analysts and investors. 
The company has been under scrutiny due to concerns about the broader regional banking sector, particularly in light of reports indicating potential deterioration in loan quality. 
However, recent reassurances from regional bank executives, including those from EFSC, have helped alleviate some of these fears, leading to a modest recovery in share prices. 
Financially, EFSC&#39;s P/E ratio stands at approximately 12.5, which is competitive compared to the industry average of around 14. 
The company&#39;s earnings per share (EPS) growth is projected at 6% year-over-year, reflecting a stable growth trajectory despite market volatility. 
Revenue forecasts suggest a slight uptick, with analysts estimating a 4% increase for the upcoming quarter, positioning EFSC favorably against peers like U.S. 
Bancorp and Texas Capital Bank, which are also navigating similar challenges. 
Upcoming earnings reports are critical for EFSC, with the third quarter results set to be released on October 27, 2025. 
Analysts anticipate a cautious performance, primarily due to the lack of key indicators that typically signal an earnings beat. 
Historical performance shows that EFSC has consistently met or exceeded expectations in previous quarters, which could play a role in shaping investor sentiment post-release. 
The consensus estimate for EPS in the upcoming report is $0.75, with a revenue estimate of $45 million. 
Given the current market conditions and the expected performance, the impact of the earnings report on EFSC&#39;s stock price could be significant, particularly if it aligns with or surpasses expectations. 
In terms of sector performance, the regional banking sector has shown signs of recovery after a turbulent period marked by investor anxiety over credit quality. 
The KBW Nasdaq Regional Banking Index has rebounded, reflecting renewed confidence among investors. 
This sector-wide recovery could provide a favorable backdrop for EFSC as it navigates its upcoming earnings report and continues to adapt to the evolving financial landscape. 
 
- Funds were net buyers of $EFSC during the previous reporting quarter. 
 
- Funds with large holdings in $EFSC include: 
 
- Maltese Capital Management LLC, MV: $4MM. Fund Rank: 57% 
www.maltesecap.com 
- GW&amp;K Investment Management LLC, MV: $2MM. Fund Rank: 76% 
 
- Point72 Asset Management LP, MV: $1MM. Fund Rank: 91% 
www.point72.com 
- Last 10 days performance: -4% 
- Last 30 days performance: -6% 
- Last 90 days performance: 0% 
 
Some of the latest news articles: 
 - Title: 1 of Wall Street’s Favorite Stock for Long-Term Investors and 2 We Ignore 
Publication Date: 10/24/2025 4:36:10 AM, Source: yahoo 
URL: https://finance.yahoo.com/news/1-wall-street-favorite-stock-043610235.html?.tsrc=rss 
 
 - Title: Enterprise Financial Services (EFSC): Reassurances Fuel Recovery—Is the Stock Still Undervalued After Sector Confidence Boost? 
Publication Date: 10/22/2025 2:11:15 AM, Source: yahoo 
URL: https://finance.yahoo.com/news/enterprise-financial-services-efsc-reassurances-021115880.html?.tsrc=rss 
 
 - Title: Are EFSC Executives&#39; Calm Signals a Turning Point for Market Trust in Regional Banks? 
Publication Date: 10/21/2025 5:10:34 PM, Source: yahoo 
URL: https://finance.yahoo.com/news/efsc-executives-calm-signals-turning-171034424.html?.tsrc=rss 
 
 - Title: Mercantile Bank (MBWM) Beats Q3 Earnings and Revenue Estimates 
Publication Date: 10/21/2025 11:05:01 AM, Source: yahoo 
URL: https://finance.yahoo.com/news/mercantile-bank-mbwm-beats-q3-110501538.html?.tsrc=rss 
 
Follow us on stocktwits.com for more earnings alerts. Not a financial advice. Not a trading signal.&quot;

Maltese Capital Management, LLC ("Maltese Capital") is a value driven, research intensive, and valuation sensitive investment firm primarily focused on financial services companies based in N. America. Since its establishment in 1996, Maltese Capital has built a strong team, led by Terry Maltese who brings over 25 years of experience in analyzing and investing in financial institutions; our experienced team of 13 research professionals has over 200 years of combined relevant experience.

Maltesecap

Maltese Capital Management, LLC

Point72 is a global asset manager led by Steven A. Cohen that deploys discretionary long/short equity, systematic, and macro investing strategies, alongside a growing portfolio of private market investments

Point72

Home - Point72

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it's important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.

Yahoo Finance

1 of Wall Street's Favorite Stock for Long-Term Investors and 2 We Ignore

Enterprise Financial Services (EFSC) shares moved higher as regional bank executives reassured investors about the health of their loan portfolios. This helped to ease recent fears of a potential credit crisis in the sector. See our latest analysis for Enterprise Financial Services.

Enterprise Financial Services (EFSC): Reassurances Fuel Recovery-Is the Stock Still Undervalued After Sector Confidence Boost?

In October 2025, investor worries about a potential credit crisis eased as regional bank CEOs, including those from Enterprise Financial Services, reported stable loan portfolio health during a period of heightened market volatility. This reassurance from industry leaders calmed jitters reminiscent of past banking turmoil and highlighted the sector's resilience in maintaining credit quality amid broader market concerns.

Are EFSC Executives' Calm Signals a Turning Point for Market Trust in Regional Banks?

Mercantile Bank (MBWM) delivered earnings and revenue surprises of +5.80% and +1.61%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Mercantile Bank (MBWM) Beats Q3 Earnings and Revenue Estimates

Stocktwits provides real-time stock, crypto & international market data to keep you up-to-date. Find top news headlines, discover your next trade idea, share & gain insights from traders and investors from around the world, build a watchlist, buy US stocks, & create and manage your portfolio.

Stocktwits

Stocktwits - Stock Market Live Quotes, Social Community Discussions, News, Stock Rankings & Earnings

StockTwits Web

Enterprise Financial Services Corp.

 "Heads up alert! Only two days until Upcoming earnings on Monday, 10/27/2025 for 

 
Neutral (5.5) 
 
In recent evaluations of Enterprise Financial Services Corp (EFSC), the stock has exhibited a mixed sentiment among analysts and investors. 
The company has been under scrutiny due to concerns about the broader regional banking sector, particularly in light of reports indicating potential deterioration in loan quality. 
However, recent reassurances from regional bank executives, including those from EFSC, have helped alleviate some of these fears, leading to a modest recovery in share prices. 
Financially, EFSC's P/E ratio stands at approximately 12.5, which is competitive compared to the industry average of around 14. 
The company's earnings per share (EPS) growth is projected at 6% year-over-year, reflecting a stable growth trajectory despite market volatility. 
Revenue forecasts suggest a slight uptick, with analysts estimating a 4% increase for the upcoming quarter, positioning EFSC favorably against peers like U.S. 
Bancorp and Texas Capital Bank, which are also navigating similar challenges. 
Upcoming earnings reports are critical for EFSC, with the third quarter results set to be released on October 27, 2025. 
Analysts anticipate a cautious performance, primarily due to the lack of key indicators that typically signal an earnings beat. 
Historical performance shows that EFSC has consistently met or exceeded expectations in previous quarters, which could play a role in shaping investor sentiment post-release. 
The consensus estimate for EPS in the upcoming report is $0.75, with a revenue estimate of $45 million. 
Given the current market conditions and the expected performance, the impact of the earnings report on EFSC's stock price could be significant, particularly if it aligns with or surpasses expectations. 
In terms of sector performance, the regional banking sector has shown signs of recovery after a turbulent period marked by investor anxiety over credit quality. 
The KBW Nasdaq Regional Banking Index has rebounded, reflecting renewed confidence among investors. 
This sector-wide recovery could provide a favorable backdrop for EFSC as it navigates its upcoming earnings report and continues to adapt to the evolving financial landscape. 
 
- Funds were net buyers of 

 during the previous reporting quarter. 
 
- Funds with large holdings in 

 include: 
 
- Maltese Capital Management LLC, MV: $4MM. Fund Rank: 57% 


 
- GW&K Investment Management LLC, MV: $2MM. Fund Rank: 76% 
 
- Point72 Asset Management LP, MV: $1MM. Fund Rank: 91% 


 
- Last 10 days performance: -4% 
- Last 30 days performance: -6% 
- Last 90 days performance: 0% 
 
Some of the latest news articles: 
 - Title: 1 of Wall Street’s Favorite Stock for Long-Term Investors and 2 We Ignore 
Publication Date: 10/24/2025 4:36:10 AM, Source: yahoo 
URL: 

 
 
 - Title: Enterprise Financial Services (EFSC): Reassurances Fuel Recovery—Is the Stock Still Undervalued After Sector Confidence Boost? 
Publication Date: 10/22/2025 2:11:15 AM, Source: yahoo 
URL: 

 
 
 - Title: Are EFSC Executives' Calm Signals a Turning Point for Market Trust in Regional Banks? 
Publication Date: 10/21/2025 5:10:34 PM, Source: yahoo 
URL: 

 
 
 - Title: Mercantile Bank (MBWM) Beats Q3 Earnings and Revenue Estimates 
Publication Date: 10/21/2025 11:05:01 AM, Source: yahoo 
URL: 